Welcome | Scientific Program | Register
Accreditation | Faculty | Special Events
Accommodations and Local Attractions | Poster Sessions and Satellite Symposia
Schedule at a Glance | Commercial Support
Exhibitor Kit

In-Practice Poster Submissions

201. Simple Programming of the GE-Centricity Electronic Medical Record Facilitates Disease Management of Hyperlipidemia
-Karen Aspry, MD

202. Dual Efficacy: A1C and LDL-C Lowering with Colesevelam HCl in Patients with Type 2 Diabetes Mellitus
-Harold Bays, MD

203. Discontinuation Rate Due to Flushing is Less Than 6% Following Therapy with a Proprietary Niacin Extended-Release
-Eliot Brinton, MD

204. Aspirin Use Prior to Initiation of Therapy With a Proprietary Niacin Extended-Release Reduces Discontinuation Rates Due to Flushing
-Eliot Brinton, MD

205. ABT-335 in Combination with Rosuvastatin Improves Multiple Lipid Ratios in Patients with Mixed Dyslipidemia
-Michael Davidson, MD

206. Long-Term Use of Colesevelam HCl Improves LDL-C and HDL-C Concentrations in Subjects with Primary Hypercholesterolemia
-Michael Davidson, MD

207. The Best Lipid Predictor
-W.E. Feeman, MD

208. Atherothrombotic Risk Factors in Women
-W.E. Feeman, MD

209. Cardiovascular Risk Profile in First Generation Southeast Asian Children and Adolescents: Comparison between Caucasian and Southeast Asian Students in the Wausau SCHOOL Project
-Erin Hanlin, BS

210. Blood Cell Fatty Acid Profiles Discriminate Acute Coronary Syndrome Case Status Better Than Standard Cardiovascular Risk Factors
-William Harris, PhD

211. Low-Density Lipoprotein Cholesterol Lowering by High-Efficacy Statins: Are Older Women at an Advantage?
-William Insull, MD

212. Statins Work Best in Those Who Need Them Most: Greater HDL-C Increase and Greater TG Reduction in Patients with Low HDL-C and/or High TG
-William Insull, MD

213. Short-Term Treatment with Ezetimibe Does Not Reduce Plasminogen Activator Inhibitor-1 Compared to Simvastatin
-Matthew Ito, PharmD

214. Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination with Rosuvastatin in Patients with Mixed Dyslipidemia: a Phase 3 Study
-Peter Jones, MD

215. Effects of ABT-335 in Combination with Rosuvastatin on Low-Density Lipoprotein Particle Size in Patients with Mixed Dyslipidemia
-Peter Jones, MD

216. Incidence of Flushing Decreases Over Time During Long-Term Therapy with a Novel Combination of Niacin Extended-Release with Simvastatin
-Richard Karas, MD

217. Effects of Niacin Extended-Release/Simvastatin Versus Simvastatin Monotherapy on Plasma Lipids in Patients with or without High Baseline Triglycerides
-Richard Karas, MD

218. Niacin Extended-Release/Simvastatin Results in Attainment of Optimal Lipid Levels in Patients Who Failed to Attain These Levels on Statin Monotherapy
-Richard Karas, MD

219. The Combination of Niacin Extended-Release with Simvastatin Improves Lipid Levels in Treatment-Naive Patients
-Richard Karas, MD

220. CDC's Lipid Standardization Program: Assuring Quality in Epidemiologic Studies for 50 Years
-Mary Kimberly, PhD

221. Effects of Prescription Omega-3-acid Ethyl Esters Plus Simvastatin on Lipids and Lipoprotein Particles in Mixed Dyslipidemia
-Kevin Maki, PhD

222. Lipoproteins in the Prediction of Coronary Artery Calcium (CAC) as Modified by Age in the Multi-Ethnic Study of Atherosclerosis (MESA)
-Pathmaja Paramsothy, M.D., M.Sc.

223. Effect of Weight Loss on Cardiometabolic Risk Using a Structured Dietary Program
-Melissa Robledo, MD

224. Effects of Colesevelam HCL on Lipoprotein Subclasses in Subjects with Type 2 Diabetes
-Robert Rosenson, MD

225. Implementation of a Coronary Artery Calcium Scoring-Based Lipid Management Program in a University Medical Center: The EDUCATE Program
-Carl Orringer, MD